Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second larges

No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere.  Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders.

Whether the challenge is entering the Japanese market for the first time, moving up the all-important ranking there by market share, or negotiating with a local in-licensing partner, this report is designed to help.

New drug pricing and price revision processes explained
Written by an acknowledged expert on the Japanese market with 20 years' experience
Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008
Incorporates all pricing rule changes that came into effect from April 2008
Pro-generic measures critically appraised
Key role of wholesalers and how they are paid clarified
Prospects for future reform to the P&R processes discussed

Table of Contents : 
Executive Summary

1. Organisation & Funding of Healthcare System
1.1 Key Actors
1.2 Health Insurance
1.2.1 Schemes Managed by the Government
1.2.2 Schemes Managed by Large Companies
1.2.3 Schemes Managed by the Municipalities
1.2.4 Health Insurance for the Elderly
1.2.5 Nursing Care Insurance
1.2.6 Health Insurance for Late Stage Seniors
1.3 Private Insurance
1.4 Healthcare Providers
1.5 Healthcare Benefits
1.6 Remuneration of Providers
1.7 Mixed Medical Care
1.8 Healthcare Expenditure
1.9 Pharmaceutical Costs

2. Regulatory Environment
2.1 Intellectual Property Protection
2.2 Regulatory Approval
2.3 Delays in Accessing the Japanese Market
2.3.1 Drug Lag
2.3.2 Vaccine Lag
2.4 Orphan Drugs
2.5 National Health Insurance Reimbursement

3. Pharmaceutical Business Environment
3.1 Market Components
3.2 Pharmaceutical Industry
3.3 Leading Companies
3.4 Leading Products
3.5 Sales and Marketing
3.6 Formulary Access
3.7 Consumption Tax
3.8 Exchange Rates
For more information please contact :

http://www.aarkstore.com/reports/Pharmaceutical-Pricing-and-Distribution-in-Japan-The-keys-to-success-in-the-world's-second-largest-market-1046.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com